[1]
|
中华医学会健康管理学分会, 中华医学会肝病学分会, 中华医学会检验医学分会. 病毒性肝炎健康管理专家共识(2021年) [J]. 中华健康管理学杂志, 2021, 15(4): 323-331.
|
[2]
|
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版) [J]. 实用肝脏病杂志, 2020, 23(1): 后插9-后插32.
|
[3]
|
Lim, L., Thompson, A., Patterson, S., George, J., Strasser, S., Lee, A., et al. (2017) Five-Year Efficacy and Safety of Tenofo-vir-Based Salvage Therapy for Patients with Chronic Hepatitis B Who Previously Failed Lam/Adv Therapy. Liver Inter-national, 37, 827-835. https://doi.org/10.1111/liv.13331
|
[4]
|
张晓强, 余建平, 盛吉芳. 替诺福韦与阿德福韦对慢性乙型肝炎患者肝功能、乙肝病毒载量及肝纤维化的临床疗效对比[J]. 中国药物应用与监测, 2021, 18(3): 147-149+164.
|
[5]
|
Rong, G., Chen, Y., Yu, Z., Li, Q., Bi, J., Tan, L., et al. (2022) Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients with Chronic Hepatitis B Treated with Entecavir: A Multicenter, Randomized, Dou-ble-Blind, Placebo-Controlled Trial. The Journal of Infectious Diseases, 225, 1091-1099. https://doi.org/10.1093/infdis/jiaa266
|
[6]
|
李薇, 邱利, 董丹丹. 富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎60例[J]. 中西医结合肝病杂志, 2022, 32(2): 128-130.
|
[7]
|
张文娟, 张静洁, 郑志兵. 乙肝治疗新药——替诺福韦艾拉酚胺半富马酸[J]. 临床药物治疗杂志, 2017, 15(3): 10-13.
|
[8]
|
Li, Z.B., Li, L., Niu, X.X., Chen, S.H., Fu, Y.M., Wang, C.Y., et al. (2021) Switching from Entecavir to Tenofovir Alafenamide for Chronic Hepatitis B Patients with Low-Level Viraemia. Liver International, 41, 1254-1264.
https://doi.org/10.1111/liv.14786
|
[9]
|
张文宏, 张大志, 窦晓光, 谢青, 江家骥, 陈新月. 聚乙二醇干扰素α治疗慢性乙型肝炎专家共识[J]. 中华肝脏病杂志, 2017, 25(9): 678-686.
|
[10]
|
Yang, J.F., Kao, Y.H., Dai, C.Y., Huang, J.F., Hsieh, M.Y., Lin, Z.Y., et al. (2010) Comparison of Adverse Effects Related to Pegylated Interferon-Based Therapy for Patients with Chronic Hepatitis B and Chronic Hepatitis C in Taiwan. Hepatology International, 4, 732-740. https://doi.org/10.1007/s12072-010-9208-0
|
[11]
|
Martinot-Peignoux, M., Lapalus, M., Maylin, S., Boyer, N., Castelnau, C., Giuily, N., et al. (2016) Baseline Hbsag and Hbcrag Titres Allow Peginterferon-Based ‘Precision Medi-cine’ in Hbeag-Negative Chronic Hepatitis B Patients. Journal of Viral Hepatitis, 23, 905-911. https://doi.org/10.1111/jvh.12565
|
[12]
|
钮志林, 朱翔, 沈伟强, 高胜利, 俞净, 赵刚, 等. 干扰素对慢性乙型肝炎患者肝细胞内Hbv cccdna、血清Hbsag、Hbv-Dna的影响研究[J]. 中华医院感染学杂志, 2014, 24(4): 792-795.
|
[13]
|
房建婷, 纪永健, 李菲菲, 孙希珍, 任万华. 阿德福韦酯序贯聚乙二醇干扰素α-2a治疗Hbeag低效价慢性乙型肝炎患者的疗效[J]. 中华传染病杂志, 2013, 31(10): 608-612.
|
[14]
|
Lu, H.Y., Zhuang, L.W., Yu, Y.Y., Si, C.W. and Li, J. (2008) Effects of Antiviral Agents on Intrahepatic CCC DNA in Hbeag-Positive Chronic Hepatitis B Patients. Chinese Journal of Hepatology, 16, 198-202.
|
[15]
|
Wieland, S., Thimme, R., Purcell, R.H. and Chisari, F.V. (2004) Genomic Analysis of the Host Response to Hepatitis B Virus Infection. Proceedings of the National Academy of Sciences of the United States of America, 101, 6669-6674.
https://doi.org/10.1073/pnas.0401771101
|
[16]
|
Kim, S.W., Yoon, J.S., Lee, M. and Cho, Y. (2022) Toward a Complete Cure for Chronic Hepatitis B: Novel Therapeutic Targets for Hepatitis B Virus. Clinical and Molecular Hepa-tology, 28, 17-30.
https://doi.org/10.3350/cmh.2021.0093
|
[17]
|
Cole, A.G. (2016) Modulators of HBV Capsid Assembly as an Ap-proach to Treating Hepatitis B Virus Infection. Current Opinion in Pharmacology, 30, 131-137. https://doi.org/10.1016/j.coph.2016.08.004
|
[18]
|
Ahn, S.H., Kim, W., Jung, Y.K., Yang, J.M., Jang, J.Y., Kweon, Y.O., et al. (2019) Efficacy and Safety of Besifovir Dipivoxil Maleate Compared with Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology, 17, 1850-1859.e4. https://doi.org/10.1016/j.cgh.2018.11.001
|
[19]
|
Belloni, L., Allweiss, L., Guerrieri, F., Pediconi, N., Volz, T., Polli-cino, T., et al. (2012) IFN-α Inhibits HBV Transcription and Replication in Cell Culture and in Humanized Mice by Tar-geting the Epigenetic Regulation of the Nuclear CCC DNA Minichromosome. The Journal of Clinical Investigation, 122, 529-537.
https://doi.org/10.1172/JCI58847
|
[20]
|
Bazinet, M., Pântea, V., Placinta, G., Moscalu, I., Cebotarescu, V., Cojuhari, L., et al. (2020) Safety and Efficacy of 48 Weeks Rep 2139 or Rep 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients with Chronic HBV Infection Naïve to Nucleos(t)ide Therapy. Gastroenterology, 158, 2180-2194.
https://doi.org/10.1053/j.gastro.2020.02.058
|
[21]
|
Birmingham, A., Anderson, E.M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., et al. (2006) 3’Utr Seed Matches, But Not Overall Identity, Are Associated with Rnai Off-Targets. Nature Methods, 3, 199-204.
https://doi.org/10.1038/nmeth854
|
[22]
|
Yuen, M.F., Schiefke, I., Yoon, J.H., Ahn, S.H., Heo, J., Kim, J.H., et al. (2020) RNA Interference Therapy with Arc-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients with Chronic Hepatitis B Infection. Hepatology, 72, 19-31. https://doi.org/10.1002/hep.31008
|
[23]
|
Schnare, M., Rollinghoff, M. and Qureshi, S. (2006) Toll-Like Receptors: Sentinels of Host Defence against Bacterial Infection. In-ternational Archives of Allergy and Immunology, 139, 75-85. https://doi.org/10.1159/000090001
|
[24]
|
Daffis, S., Balsitis, S., Chamberlain, J., Zheng, J., Santos, R., Rowe, W., et al. (2021) Toll-Like Receptor 8 Agonist Gs-9688 In-duces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B. Hepatology, 73, 53-67.
https://doi.org/10.1002/hep.31255
|
[25]
|
Godon, O., Fontaine, H., Kahi, S., Meritet, J.F., Scott-Algara, D., Pol, S., et al. (2014) Immunological and Antiviral Responses after Therapeutic DNA Immunization in Chronic Hepatitis B Patients Efficiently Treated by Analogues. Molecular Therapy, 22, 675-684. https://doi.org/10.1038/mt.2013.274
|
[26]
|
Bertoletti, A. and Le Bert, N. (2018) Immunotherapy for Chronic Hepati-tis B Virus Infection. Gut and Liver, 12, 497-507. https://doi.org/10.5009/gnl17233
|